The role of combined treatment of prostatic gland after biopsy of the prostate for an elevated PSA level


Cite item

Full Text

Abstract

Benign prostatic hyperplasia and prostatic cancer have a significant effect of men's health, quality of life and death rate. Recent researches propose algorithms for treatment of benign prostatic hyperplasia which help determine optimal management of the disease using either alpha-adrenoblocker or combined therapy basing on factors of progression risk. Molecular-genetic, biological investigations reveal pathological prosesses leading to onset of the above pathological conditions thus opening prospects for prophylaxis of both benign and malignant prostatic hyperplasia. Further studies will specify efficacy and safety of 5-alpha reductase inhibitors in prevention of prostatic cancer.

About the authors

V E Okhrits

A B Bogdanov

E I Veliev

References

  1. Trachtenberg J. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression. Br. J. Urol. Int. 2005; 95 (suppl. 4): 6-11.
  2. Bostwick D. G. et al. The association of benign prostatic hyperplasia and cancer of the prostate. Cancer 1992; 70 (suool. 1): 291-301.
  3. Alcaraz A. et al. Is there evidence of a relation between benign prostatic hyperplasia and prostate cancer? Eur. Urol. 2009; 55: 864-875.
  4. Sakr W. A., Grignon D. J., Crissman J. D. et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994; 8: 439-443.
  5. Hammarsten J. et al. Calculated fast-growing benign prostatic hyperplasia - a risk factor for developing clinical prostate cancer. Scand. J. Urol. Nephrol. 2002; 36: 330-338.
  6. Briganti A. et al. Prostate volume and adverse prostate cancer features: fact not artifact. Eur. J. Cancer 2007; 43: 2669-2677.
  7. Emberton M. et al. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk. Br. J. Urol. Int. 2007; 100: 249-253.
  8. McConnell J. D. et al. MTOPS Steering Committee. The impact of medical therapy on the clinical progression of BPH: Results of the MTOPS trial. J. Urol. (Baltimore) 2002; 167: A1042.
  9. Jeong Y. B. et al. Effect of discontinuation of 5alpha-reductase inhibitors on prostate volume and symptoms in men with BPH: a prospective study. Urology 2009; 73 (4): 802-806.
  10. Thompson I. M. et al. Finasteride decreases the risk of prostatic intraepithelial neoplasia. J. Urol. (Baltimore) 2007; 178 (1): 107-109.
  11. Rittmaster R. et al. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. Urology 2008; 72: 808-912.
  12. Eggener S. E. et al. Enhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model. Prostate 2006; 66: 495-502.
  13. Thompson I. M. et al. The influence of finasteride in the development of prostate cancer. N. Engl. J. Med. 2003; 349: 215- 224.
  14. Cohen Y. C. et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the prostate cancer prevention trial. J. Natl. Cancer Inst. 2007; 99: 1366-1374.
  15. Pinsky P., Parnes H., Ford L. Estimating rates of true highgrade disease in the prostate cancer prevention trial. Cancer Prev. Res. 2008; 1: 182-186.
  16. Redman M. W. et al. Finasteride does not increase the risk of highgrade prostate cancer: a bias-adjusted modeling approach. Cancer Prev. Res. 2008; 1: 182-186.
  17. Svatek R. S., Lee J. J., Roehrborn C. G. et al. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer 2008; 112: 1058-1065.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies